469 related articles for article (PubMed ID: 15514991)
1. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
3. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
Jacob C; Martin-Chouly C; Lagente V
Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
[TBL] [Abstract][Full Text] [Related]
4. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
5. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
6. Optimization and validation of a reporter gene assay for screening of phosphodiesterase inhibitors in a high throughput system.
Nanda K; Chatterjee M; Arya R; Mukherjee S; Saini KS; Dastidar S; Ray A
Biotechnol J; 2008 Oct; 3(9-10):1276-9. PubMed ID: 18655041
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.
Ekholm D; Hemmer B; Gao G; Vergelli M; Martin R; Manganiello V
J Immunol; 1997 Aug; 159(3):1520-9. PubMed ID: 9233651
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
10. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
11. Participation of peripheral and spinal phosphodiesterases 4 and 5 in inflammatory pain.
Torres-López JE; Argüelles CF; Granados-Soto V
Proc West Pharmacol Soc; 2002; 45():141-3. PubMed ID: 12434560
[No Abstract] [Full Text] [Related]
12. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
13. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
15. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
Chambers RJ; Abrams K; Castleberry TA; Cheng JB; Fisher DA; Kamath AV; Marfat A; Nettleton DO; Pillar JD; Salter ED; Sheils AL; Shirley JT; Turner CR; Umland JP; Lam KT
Bioorg Med Chem Lett; 2006 Feb; 16(3):718-21. PubMed ID: 16263279
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
19. The potential of PDE4 inhibitors in asthma or COPD.
Spina D
Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
[TBL] [Abstract][Full Text] [Related]
20. Multiple cAMP Phosphodiesterases Act Together to Prevent Premature Oocyte Meiosis and Ovulation.
Vigone G; Shuhaibar LC; Egbert JR; Uliasz TF; Movsesian MA; Jaffe LA
Endocrinology; 2018 May; 159(5):2142-2152. PubMed ID: 29608743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
